Generolon, spray 5% 60 ml 3 pcs

A remedy for the treatment of alopecia. It has a stimulating effect on hair growth in men and women with androgenic alopecia (male pattern baldness). Appearance of signs of hair growth is observed after 4 months or more of using the drug 2 times a day. The onset and severity of the effect may vary from patient to patient. After discontinuation of minoxidil the growth of new hair is suspended, and after 3-4 months it is possible to restore the initial appearance.

The exact mechanism of action of minoxidil as a hair growth stimulator in patients with androgenic alopecia is unknown.
When used systemically, minoxidil has a vasodilatory effect. No systemic side effects associated with systemic absorption of minoxidil have been observed in controlled clinical studies following external administration of minoxidil in patients with both normal and elevated BP.

Pharmacokinetics

When applied externally, minoxidil is poorly absorbed through normal intact skin: on average, 1.4% (0.3-4.5%) of the total dose applied enters the systemic bloodstream. When applied externally, the serum concentration of minoxidil is determined by its rate of absorption through the skin. After discontinuation of use, approximately 95% of minoxidil that has undergone systemic absorption is eliminated within 4 days.

Indications

Active ingredient

Composition

Associates:

Ethanol 96% – 243 mg,

Propylene glycol – 520 mg,

Water – up to 1 ml.

Interaction

Directions for use

Special Instructions

In case of systemic side effects (chest pain, palpitations, dizziness, decreased blood pressure, sudden weight gain, swelling of hands and/or feet) and redness and irritation at the injection site, minoxidil should be stopped and appropriate therapy administered if necessary.

In some patients, changes in hair color and texture have been observed after minoxidil use.

Contraindications

Side effects

Dermatological reactions: often – redness, itching, peeling of the scalp; in some cases – hypertrichosis (unwanted body hair growth, including facial hair growth in women).

There may be increased hair loss during the transition from the resting phase to the hair growth phase (this temporary phenomenon is observed 2-6 weeks after the start of therapy and gradually, within 2 weeks, it stops).

Cardiovascular system disorders: in some cases – arterial hypotension.

Pregnancy use

Similarities